Inhibitor Therapeutics Files Q1 2025 10-Q
Ticker: INTI · Form: 10-Q · Filed: May 14, 2025 · CIK: 1042418
| Field | Detail |
|---|---|
| Company | Inhibitor Therapeutics, Inc. (INTI) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
Related Tickers: INTI
TL;DR
INTI 10-Q filed: Q1 2025 financials out, shows preferred & common stock data.
AI Summary
Inhibitor Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as HedgePath Pharmaceuticals, Inc. and COMMONWEALTH BIOTECHNOLOGIES INC, is based in Tampa, Florida. The filing details financial information, including preferred stock series and common stock data as of March 31, 2025, and comparative periods.
Why It Matters
This filing provides investors with the latest financial snapshot of Inhibitor Therapeutics, Inc., crucial for understanding the company's current financial health and strategic positioning.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags or significant new disclosures.
Key Numbers
- 001-13467 — SEC File Number (Identifies the company's registration with the SEC.)
- 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)
Key Players & Entities
- Inhibitor Therapeutics, Inc. (company) — Filer
- HedgePath Pharmaceuticals, Inc. (company) — Former company name
- COMMONWEALTH BIOTECHNOLOGIES INC (company) — Former company name
- 20250331 (date) — Period of report
- 20250514 (date) — Filing date
FAQ
What is the company's primary business activity as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When was the company's most recent name change?
The company's name was changed from HedgePath Pharmaceuticals, Inc. on August 16, 2013.
What is the reporting period for this 10-Q filing?
The conformed period of report for this 10-Q filing is March 31, 2025.
What types of preferred stock are mentioned in the filing as of March 31, 2025?
The filing mentions Series A Preferred Stock, Series B Convertible Preferred Stock, and Undesignated Preferred Stock as of March 31, 2025.
What is the company's business address?
The company's business address is 4830 W. KENNEDY BLVD., SUITE 600, TAMPA, FL 33609.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Inhibitor Therapeutics, Inc. (INTI).